Related Experiment Video

Updated: May 27, 2026

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

GLUT4 associated proteins as therapeutic targets for diabetes

Broden J Morgan1, Siew Yeen Chai, Anthony L Albiston

  • 1Florey Neurosciences Institutes, University of Melbourne, Parkville, Victoria, 3010, Australia.

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
|November 15, 2011
PubMed

Insights

This review explores glucose transporter type 4 (GLUT4) trafficking in type 2 diabetes. It highlights patented therapeutic targets for enhancing GLUT4 translocation and improving glucose uptake.

Area of Science:

  • Metabolic diseases
  • Molecular biology
  • Endocrinology

Background:

  • Type 2 diabetes involves insulin resistance and impaired insulin secretion.
  • Insulin regulates blood sugar by promoting glucose uptake via GLUT4 transporter.
  • GLUT4 translocation to the cell membrane is crucial for glucose homeostasis.

Purpose of the Study:

  • To review GLUT4 trafficking mechanisms in type 2 diabetes.
  • To identify patented therapeutic targets associated with GLUT4.
  • To explore novel strategies for diabetes treatment.

Main Methods:

  • Literature review of GLUT4 trafficking.
  • Analysis of patents related to GLUT4 associated proteins.
  • Overview of signal transduction pathways regulating GLUT4.

Main Results:

  • Detailed overview of GLUT4 trafficking pathways.
  • Identification of patented proteins and methods targeting GLUT4.
  • Potential for insulin-independent GLUT4 translocation strategies.

Conclusions:

  • GLUT4 associated proteins represent promising therapeutic targets for diabetes.
  • Novel approaches focus on enhancing GLUT4 levels and translocation.
  • Patented inventions offer new avenues for type 2 diabetes treatment.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.